Discovery of hybrid dual N-acylhydrazone and diaryl urea derivatives as potent antitumor agents: Design, synthesis and cytotoxicity evaluation

Molecules

Volumn 18, Issue 3, 2013, Pages 2904-2923

  Zhai, Xin ^a   Huang, Qiang ^a   Jiang, Nan ^a   Wu, Di ^a   Zhou, Hongyu ^a   Gong, Ping ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cytotoxicity; Diaryl ureas; N acylhydrazone

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; HYDRAZONE DERIVATIVE; UREA;

ARTICLE; CELL STRAIN HL 60; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; HUMAN; IC 50; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; HYDRAZONES; INHIBITORY CONCENTRATION 50; UREA;

EID: 84875619442     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18032904     Document Type: Article

References (14)

1. Keating, G.M.; Santoro, A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 2009, 69, 223-240.
2. Wilhelm, S.M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J.M.; Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7, 3129-3140.
3. Smalley, K.S.; Xiao, M.; Villanueva, J.; Nguyen, T.K.; Flaherty, K.T.; Letrero, R.; van Belle, P.; Elder, D.E.; Wang, Y.; Nathanson, K.L.; et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009, 28, 85-94.
4. Adnane, L.; Trail, P.A.; Taylor, I.; Wilhelm, S.M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006, 407, 597-612.
5. Hyun, Y.W.; Jeong, H. Sorafenib in liver cancer. Expert Opin. Pharmacother. 2012, 13, 1059-1067.
6. Strumberg, D. Sorafenib for the treatment of renal cancer. Expert Opin. Pharmacother. 2012, 13, 407-419.
7. Peterson, Q.P.; Hsu, D.C.; Goode, D.R.; Novotny, C.J.; Totten, R.K.; Hergenrother, P.J. Procaspase-3 activation as an anti-cancer strategy: Structure-activity relationship of PAC-1, and its cellular co-localization with caspase-3. J. Med. Chem. 2009, 52, 5721-5731.
8. Lucas, P.W.; Schmit, J.M.; Peterson, Q.P.; West, D.C.; Hsu, D.C.; Novotny, C.J.; Dirikolu, L.; Churchwell, M.I.; Doerge, D.R.; Garrett, L.D.; et al. Pharmacokinetics and Derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs. Invest. New Drugs 2011, 29, 901-911.
9. Peterson, Q.P.; Goode, D.R.; West, D.C.; Ramsey, K.N.; Lee, J.J.; Hergenrother, P.J. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J. Mol. Biol. 2009, 388, 144-158.
10. Zhang, B.; Zhao, Y.; Zhai, X.; Wang, L.; Yang, J.; Tan, Z.; Gong, P. Design, synthesis and anticancer activities of diaryl urea derivatives bearing N-acylhydrazone moiety. Chem. Pharm. Bull. 2012, 60, 1046-1054.
11. Putt, K.S.; Chen, G.W.; Pearson, J.M.; Sandhorst, J.S.; Hoagland,M.S.; Kwon, J.T.; Hwang, S.K.; Jin, H.; Churchwell, M.I.; Cho, M.H.; et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Biol. 2006, 2, 543-550.
12. Kudo, M.; Hanashima, T.; Muranaka, A.; Sato, H.; Uchiyama, M.; Azumaya, I.; Hirano, T.; Kagechika, H.; Tanatani, A. Identification of Absolute Helical Structures of Aromatic Multilayered Oligo(m-Phenylurea)s in Solution. J. Org. Chem. 2009, 74, 8154-8163.
13. Duff, J.C.; Bills, E.J. Reactions between Hexamethylenetetramine and Phenolic Compounds. Part I. A New Method for the Preparation of 3- and 5-Aldehydosalicylic Acids. J. Chem. Soc. 1932, 1932, 1987-1988.
14. Muccioli, G.G.; Fazio, N.; Scriba, G.K.; Poppitz, W.; Cannata, F.; Poupaert, J.H.; Wouters, J.; Lambert, J.D. Substituted 2-Thioxoimidazolidin-4- Ones and Imidazolidine-2,4-Diones as Fatty Acid Amide Hydrolase Inhibitors Templates. J. Med. Chem. 2006, 49, 417-425.